Emerging Biomarkers in Cardiology

The landscape of cardiac biomarkers is shifting from simple “damage detection” (like Troponin) to “pathophysiological profiling.” For a clinician focusing on diagnostics, the most relevant newer biomarkers are those that help phenotype complex conditions like HFpEF, ATTR-CM, and PVC-induced cardiomyopathy.

1. Advanced Heart Failure & Myocardial Remodeling

While NT-proBNP remains the workhorse, newer markers provide insights into fibrosis and mechanical strain, which are crucial for prognosticating patients who may be “biochemically stable” but structurally worsening.

• Soluble ST2 (sST2): A marker of mechanical stretch and fibrosis. Unlike BNP, it is remarkably stable, not significantly affected by age, BMI, or renal function. High levels (>35 ng/mL) strongly predict hospitalization and death across HFrEF and HFpEF.
• Galectin-3: Reflects active macrophage-mediated fibrosis. It is particularly useful for identifying patients who will experience rapid remodeling.
• MR-proADM (Mid-regional pro-adrenomedullin): A major 2026 update (Circulation 31 March 2026) highlights its utility in Transthyretin Amyloid Cardiomyopathy (ATTR-CM). MR-proADM is a superior predictor of mortality and heart failure events in ATTR-CM compared to traditional markers.
• GDF-15 (Growth Differentiation Factor-15): A “stress-response” cytokine linked to inflammation and oxidative stress. It is increasingly used in multi-marker panels to predict bleeding risk in patients on anticoagulants and overall mortality in chronic heart failure.

2. Arrhythmias & PVC-Induced Cardiomyopathy

There is emerging data on how to predict which patients with a high PVC burden will develop LV dysfunction.

• Inflammatory Transcriptional Markers: Research published in January 2026 (Circulation: Arrhythmia and Electrophysiology) suggests that high PVC burden upregulates IL-1β and the NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) signaling pathway. These markers of “smoldering inflammation” may soon provide a biochemical rationale for early ablation in asymptomatic patients with a high burden before LVEF drops.
• MicroRNAs (miRNA-208b, miRNA-9): Being studied as specific markers for ventricular remodeling that could differentiate “benign” PVCs from those causing structural damage at a molecular level. A recent report noted that these miRNAs may serve as early predictive biomarkers for Pacing Induced Cardiomyopathy. Early deterioration of left ventricular global longitudinal strain and expression of these miRNAs preceded overt left ventricular systolic dysfunction.

3. Valvular & Structural Heart Disease

• Lipoprotein(a) in Aortic Stenosis: Beyond its role in atherosclerosis, high Lp(a) is now recognized as a primary driver of calcific aortic valve disease progression. In patients with calcific aortic stenosis, Lp(a) levels predicted a higher risk of valvular and cardiovascular outcomes (JAHA 2025).
• Matrix Metalloproteinases (MMP‐9): Used as an exploratory marker for extracellular matrix turnover, providing a window into the “transition” from compensated hypertrophy to heart failure in patients with severe AS.

4. The Multi-Omics & AI Frontier

The “newer” biomarker is often not a single protein, but a proteomic or metabolomic signature.

• Proteomic Panels: Instead of one marker, researchers are now validating panels of 50+ proteins. These signatures can predict the 10-year risk of a Major Adverse Cardiovascular Event (MACE) more accurately than clinical risk scores.
• Gut Microbiome Metabolites (TMAO): Trimethylamine N-oxide (TMAO) is gaining traction as a biomarker for gut-heart axis health, directly linked to plaque stability and heart failure outcomes.

Summary Table for Clinical Application

Pathophysiology	Biomarker	Clinical Utility
Myocardial Strain	sST2	Prognosis in HF; independent of renal function.
Active Fibrosis	Galectin-3	Predicts rapid LV remodeling and HFpEF progression.
Systemic Stress	GDF-15	Risk stratification for bleeding/mortality.
Amyloidosis (ATTR)	MR-proADM	Predictive of mortality in cardiac amyloidosis (2026 update).
Early Ischemia	Copeptin	Used with hs-cTn for rapid “one-draw” rule-out of MI.